Sartorius AG · XETR:SRT
Sartorius — Sartorius Stedim Biotech — Investor Presentation (April 2025)
37 slides from Sartorius's investor presentation, April 2025
Slide 1: Simplifying Progress: Sartorius Stedim Biotech Investor Presentation
Simplifying Progress Sartorius Stedim Biotech Investor Presentation April 2025
Slide 2: Agenda
Sartorius Stedim Biotech Group Agenda Overview | Strategy Q1 2025 Results | FY 2025 Guidance Appendix 2
Slide 3: Sartorius Stedim Biotech at a glance
Sartorius Stedim Biotech Group Sartorius Stedim Biotech at a glance ~€2.8bn Sales revenue ~15% Our mission Sales CAGR 2014-2024 ~28.0% EBITDA margin1 We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling ~80% the development of new and be
Slide 4: Track record of profitable sales growth above market
Sartorius Stedim Biotech Group Track record of profitable sales growth above market Sales revenue; EBITDA margin1 CAGR 15% ▪ Increase Increase share ofshare of wallet wallet by by ~€2.8bn addressing addressing criticalcritical stepssteps at customers at customers ▪ Strong focus on recurring revenue
Slide 5: Covering most steps of the biopharmaceutical manufacturing process
Sartorius Stedim Biotech Group Covering most steps of the biopharmaceutical manufacturing process ▪ Differentiated by the range and completeness of the Culture media Seed Scale-up Production portfolio preparation cultivation ▪ Excellent positioning in key single-use technologies UPSTREAM ▪ Internati
Slide 6: Pioneer and leader in the growing single-use technology market
Sartorius Stedim Biotech Group Pioneer and leader in the growing single-use technology market Single-use market penetration expected to increase from ~35% to ~75% ▪ Single-use products offer advantages over conventional stainless-steel devices ▪ Capex|Opex reduction over entire lifecycle ▪ Reduced r
Slide 7: Competitive product offering
Sartorius Stedim Biotech Group Competitive product offering Sartorius Merck | Danaher Thermo Top 3 Players Millipore Fisher All player with approx. Filtration equal market shares 1. Sartorius Fluid 2. Thermo Fisher Management 3. Merck | Millipore 1. Sartorius Fermentation 2. Thermo Fisher 3. Danaher
Slide 8: Generating revenue throughout the lifecycle of a biopharma drug
Sartorius Stedim Biotech Group Generating revenue throughout the lifecycle of a biopharma drug Products specified into customers’ validated processes; recurring revenues with Attractive business consumables after approval of the drug by health authorities (e.g. FDA, EMA) model Stage Pre-clinical Cli
Slide 9: Limited dependence on individual accounts
Sartorius Stedim Biotech Group Limited dependence on individual accounts Long-term business relationships with leading Limited dependence on individual accounts global (bio-) pharma companies Sales to Top 50 customers in 2024, € in millions 1000 800 ~51% ~55% ~46% 600 ~38% ~25% 400 200 0 Top 10 11 t
Slide 10: Resilient global setup, well prepared for further growth
Sartorius Stedim Biotech Group Resilient global setup, well prepared for further growth Capex 474 Capex Major projects ~X% Global 340 in millions of €; composition resilience ratio in % 17.1 Regular expansion ~3% 12.2 Capitalized R&D ~2% Redundant Maintenance ~3% capacities 2023 2024 Freiburg, Germa
Slide 11: Attractive market environment offers strong growth opportunities
Sartorius Stedim Biotech Group Attractive market environment offers strong growth opportunities Growing and aging population Biologics are gaining importance2 >9.5 billion people by 20501 World population over age 65 in 2050 Sales share of biologics in 2028 ~1.6bn ~45% ~10% CAGR³ biopharma market 20
Slide 12: Addressing customer needs across all types of biopharma drugs
Sartorius Stedim Biotech Group Addressing customer needs across all types of biopharma drugs 1796 1818 1982 1986 2012 / 2017 2020 2023 Blood Recombinant Monoclonal Cell & gene mRNA CRISPR Vaccines products proteins antibodies therapies vaccines gene therapy Established Biopharmaceuticals Next Genera
Slide 13: Fundamental biopharma growth drivers intact, new modalities add dynamics
Sartorius Stedim Biotech Group Fundamental biopharma growth drivers intact, additional dynamics from the new modalities segment ~30% of biopharma pipeline is focusing on CGT1 Pillars of growth CAGRs 2022–20273 Pharma market ~3-6% ~70% ~30% Biopharma market ~10% Other CGT biologics Biosimilars ~15% C
Slide 14: Extensive technology platform for cell and gene therapy applications
Sartorius Stedim Biotech Group Extensive technology platform for cell and gene therapy applications Biological Albumedix Polyplus CellGenix Xell Up & downstream solutions Industries Cell culture Growth factors Media and Recombinant Transfection Cell line development, media and cytokines supplements
Slide 15: Biosimilars: Strong growth, big opportunities
Sartorius Stedim Biotech Group Biosimilars: Strong growth, big opportunities Major blockbuster biologics are going off-patent Time-to-market is key as only the first providers are most likely profitable Several approvals in Asia and Europe; U.S. at the beginning For now, relatively small market but
Slide 16: High innovation dynamics in Biopharma
Sartorius Stedim Biotech Group High innovation dynamics in Biopharma Development of new Increased efficiency New tools and Future drug drugs and vaccines possible in the methods required manufacturing is must be accelerated, production of 'classic' e.g. for novel cell and more automated, e.g. throug
Slide 17: Integration of innovative technologies is a Sartorius core competency
Sartorius Stedim Biotech Group Integration of innovative technologies is a Sartorius core competency Acquisitions Cooperations Own Product Development of complementary technologies with partners leading in their fields in areas of core competencies Cell cultivation Process Separation Artificial tech
Slide 18: Consistent M&A strategy focusing on two defined areas
Sartorius Stedim Biotech Group Consistent M&A strategy focusing on two defined areas Unique portfolio for Intensified technologies Advanced Therapies for downstream processing Biological WaterSep Danaher chromatography BIA Separations CellGenix (2020) (2020) Industries (2020) (2021) (2019) Albumedix
Slide 19: Leveraging digital tools for faster process development
Sartorius Stedim Biotech Group Leveraging digital tools for faster process development and cost- efficient bioprocessing Combination of bioprocess sensors, analyzers and software to… Expected high …collect, monitor and control quality- Faster results New insights impact of AI, in- critical parameter
Slide 20: Midterm outlook to 2028: Expect to continue outgrowing the market
Sartorius Stedim Biotech Group Midterm outlook to 2028: Expect to continue outgrowing the market Sales Revenue CAGR Low to mid-teens range to 2028 thereof ~1/5 from acquisitions Underlying EBITDA above 35 % Margin in 2028 ▪ Margin target includes expenses for reduction of the company’s CO2 emission
Slide 21: Agenda
Sartorius Stedim Biotech Group Agenda Overview | Strategy Q1 2025 Results | FY 2025 Guidance Appendix 21
Slide 22: Significant profitable growth in Q1
Sartorius Stedim Biotech Group Significant profitable growth in Q1 Sartorius Stedim Biotech Group Q1 2024 Q1 2025 in % in % cc1 in millions of € unless otherwise specified Sales revenue 667 745 +11.7 +10.4 Underlying EBITDA2 191 229 +19.9 Underlying EBITDA2 margin in % 28.6 30.8 +2.2pp Underlying EP
Slide 23: Growth in all regions
Sartorius Stedim Biotech Group Growth in all regions EMEA Americas Asia|Pacific Sales by region Sales | € in millions Sales | € in millions Sales | € in millions in % +8.9% +13.8% +7.8% EMEA Americas ~ 42% ~ 37% 311 284 274 233 €745m 149 160 Asia|Pacific Q1 2024 Q1 2025 Q1 2024 Q1 2025 Q1 2024 Q1 20
Slide 24: Overproportionate increase of net profit and cash flow KPIs
Sartorius Stedim Biotech Group Overproportionate increase of net profit and cash flow KPIs Sartorius Stedim Biotech Group Q1 2024 Q1 2025 in % in millions of € unless otherwise specified Underlying net profit1,2 84 113 +34.5 ▪ Strong increase of operating cash flow due to higher earnings, lower tax
Slide 25: Further deleveraging as planned
Sartorius Stedim Biotech Group Further deleveraging as planned Key financial indicators Net debt and net debt to underlying EBITDA Sartorius Stedim Biotech Group Dec. 31, Mar. 31, 4,000 6.0 in millions of € unless otherwise specified 2024 2025 5.0 3,000 Equity ratio in % 48.7 48.3 4.0 2,000 3.0 Net
Slide 26: Current situation regarding tariffs
Sartorius Stedim Biotech Group Current situation regarding tariffs: No impact on competitive position; mitigating actions underway to limit effects on profit Limited direct impact on top-line ▪ Mission-critical products spec'd into validated processes at customers; low price elasticity ▪ All players
Slide 27: 2025 guidance: Robust sales revenue growth and profitability
Sartorius Stedim Biotech Group 2025 guidance: Robust sales revenue growth and profitability Guidance 20251 Sales revenue growth Underlying EBITDA margin Sartorius Stedim Biotech Group + ~7% (+/- 2pp) ~30% to ~31% ▪ Capex ratio of around 13% ▪ Net debt/ul. EBITDA to decrease to approx. 2.5 at year-en
Slide 28: Appendix
28 Appendix SARTORI
Slide 29: Reasons to invest
Sartorius Stedim Biotech Group Reasons to invest Clear strategy, Strong fundamental Competitive, consistent growth drivers differentiated implementation product portfolio High-performance, High share of Ambitious team, resilient production recurring revenues strong customer focus and R&D infrastruct
Slide 30: Board of Sartorius Stedim Biotech S.A. group
Sartorius Stedim Biotech Group Board of Sartorius Stedim Biotech S.A. group Dr. Dr. René Romaine Pascale Susan Cecile Anne-Marie Lothar Christopher Share of Joachim Fáber Fernandes Boissel Dexter Dussart Graffin Kappich Nowers independent Kreuzburg CEO Employee members Chairman Representative Audit
Slide 31: A sampling of the product portfolio
Sartorius Stedim Biotech Group A sampling of the product portfolio Filtration Purification Fermentation Fluid management 31
Slide 32: Single-use allows manufacturers to mitigate investment risks
Sartorius Stedim Biotech Group Single-use allows manufacturers to mitigate investment risks ▪ Construction of stainless-steel based facilities takes longer and is more complex compared to single-use ▪ Therefore, investment in stainless-steel facilities has to start in early clinical phase II ▪ The c
Slide 33: Share price performance
Sartorius Stedim Biotech Group Share price performance 600% 400% 200% 0% Mar-20 Mar-21 Mar-22 Mar-23 Mar-24 Mar-25 Jul-20 Jul-21 Jul-22 Jul-23 Jul-24 Jan-24 Jan-20 Sep-20 Jan-21 Sep-21 Jan-22 Sep-22 Jan-23 Sep-23 Sep-24 Jan-25 May-20 Nov-20 May-21 Nov-21 May-22 Nov-22 May-23 Nov-23 May-24 Nov-24 Sar
Slide 34: Corporate responsibility & further financial information
Sartorius Stedim Biotech Group Corporate responsibility & further financial information To Sartorius, sustainability means operating responsibly over the long term – with respect to Please click below for further financial information: business partners, employees and society as well as to natural r
Slide 35: Contacts and Financial calendar
Sartorius Stedim Biotech Group Contacts and Financial calendar ▪ May 21, 2025 Roadshow, London Petra Kirchhoff Head of Corporate Communications & IR ▪ May 22, 2025 Barclays European Leaders Conference, London +49.551.308.1686 petra.kirchhoff@sartorius.com ▪ May 28, 2025 dbAccess European Champions C
Slide 36: Disclaimer
Sartorius Stedim Biotech Group Disclaimer This presentation contains statements concerning the future performance of the Sartorius Stedim Biotech Group. These statements are based on assumptions and estimates. Although we are convinced that these forward- looking statements are realistic, we cannot
Slide 37: Simplifying Progress
Simplifying Progress Scan or click here to visit our IR website.
Sartorius Stedim Biotech — Investor Presentation (April 2025) on 6ix